Abivax SA
PAR:ABVX
Abivax SA
Other Items
Abivax SA
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abivax SA
PAR:ABVX
|
Other Items
€3.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Other Items
€3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Other Items
-€241k
|
CAGR 3-Years
58%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
25%
|
|
|
Inventiva SA
PAR:IVA
|
Other Items
-€24.6m
|
CAGR 3-Years
-59%
|
CAGR 5-Years
-90%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Other Items
$584k
|
CAGR 3-Years
58%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Other Items
-€8m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
Abivax SA
Glance View
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
See Also
What is Abivax SA's Other Items?
Other Items
3.7m
EUR
Based on the financial report for Jun 30, 2025, Abivax SA's Other Items amounts to 3.7m EUR.
What is Abivax SA's Other Items growth rate?
Other Items CAGR 5Y
27%
Over the last year, the Other Items growth was -52%.
